LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 4 of total 4

Search options

  1. Article ; Online: Daratumumab-based induction and autologous transplantation in concomitant multiple myeloma and chronic myeloid leukemia.

    Liberatore, Carmine / Fioritoni, Francesca / Natale, Annalisa / Montanaro, Guido / La Barba, Gaetano / Passeri, Cecilia / Iuliani, Ornella / Fabi, Bianca / Baldoni, Stefano / Fantasia, Donatella / Calabrese, Giuseppe / Accorsi, Patrizia / Santarone, Stella / Pulini, Stefano / Di Ianni, Mauro

    EJHaem

    2023  Volume 4, Issue 4, Page(s) 1152–1156

    Abstract: The coexistence of chronic myeloid leukemia (CML) and multiple myeloma (MM) is a rare clinical condition. By means of FISH and molecular analysis on both sorted CD138 plasma cells and cryopreserved CD34 stem cells, a distinct clonal origin of the ... ...

    Abstract The coexistence of chronic myeloid leukemia (CML) and multiple myeloma (MM) is a rare clinical condition. By means of FISH and molecular analysis on both sorted CD138 plasma cells and cryopreserved CD34 stem cells, a distinct clonal origin of the hematological malignancies was demonstrated in our case. We report on the first patient diagnosed with CML and MM treated with daratumumab, bortezomib, thalidomide, and dexamethasone (Dara-VTd) induction, stem-cell collection, and autologous stem cell transplantation (ASCT). The co-administration of Dara-VTd and imatinib proved feasible and highly effective in the management of both CML and MM. Despite concerns with stem cell mobilization and collection in patients exposed to daratumumab, in our experience the use of higher cyclophosphamide dose 4 g/m
    Language English
    Publishing date 2023-09-11
    Publishing country United States
    Document type Case Reports
    ISSN 2688-6146
    ISSN (online) 2688-6146
    DOI 10.1002/jha2.765
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  2. Article ; Online: Higher cyclophosphamide dose grants optimal stem cell collection after daratumumab-based induction in multiple myeloma.

    Liberatore, Carmine / Perini, Tommaso / Passeri, Cecilia / Ferla, Valeria / Fioritoni, Francesca / Girlando, Virginia / Iuliani, Ornella / Orsini, Alessia / Montanaro, Guido / Farina, Francesca / Di Nicola, Alessandro / Nitti, Rosamaria / Pulini, Stefano / Mastaglio, Sara / Santarone, Stella / Coppola, Milena / Marktel, Sarah / Accorsi, Patrizia / Ciceri, Fabio /
    Marcatti, Magda / Di Ianni, Mauro

    Haematologica

    2023  Volume 108, Issue 12, Page(s) 3502–3505

    MeSH term(s) Humans ; Multiple Myeloma/drug therapy ; Cyclophosphamide/therapeutic use ; Antibodies, Monoclonal/therapeutic use ; Stem Cells ; Antineoplastic Combined Chemotherapy Protocols ; Dexamethasone/therapeutic use
    Chemical Substances daratumumab (4Z63YK6E0E) ; Cyclophosphamide (8N3DW7272P) ; Antibodies, Monoclonal ; Dexamethasone (7S5I7G3JQL)
    Language English
    Publishing date 2023-12-01
    Publishing country Italy
    Document type Journal Article
    ZDB-ID 2333-4
    ISSN 1592-8721 ; 0017-6567 ; 0390-6078
    ISSN (online) 1592-8721
    ISSN 0017-6567 ; 0390-6078
    DOI 10.3324/haematol.2023.283452
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.76: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Treatment of Philadelphia-negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factors.

    Andriani, Alessandro / Elli, Elena / Trapè, Giulio / Villivà, Nicoletta / Fianchi, Luana / Di Veroli, Ambra / Niscola, Pasquale / Centra, Antonia / Anaclerico, Barbara / Montanaro, Guido / Martini, Vincenza / Aroldi, Andrea / Carmosino, Ida / Voso, Maria Teresa / Breccia, Massimo / Montanaro, Marco / Foà, Roberto / Latagliata, Roberto

    Hematological oncology

    2019  Volume 37, Issue 3, Page(s) 291–295

    Abstract: There have been some reports on a possible role of azacytidine (AZA) in the treatment of accelerated/blastic phase evolved from Philadelphia-negative myeloproliferative neoplasms (MPN-AP/BP), but results are conflicting. In this study, we analyzed a ... ...

    Abstract There have been some reports on a possible role of azacytidine (AZA) in the treatment of accelerated/blastic phase evolved from Philadelphia-negative myeloproliferative neoplasms (MPN-AP/BP), but results are conflicting. In this study, we analyzed a cohort of 39 patients with MPN-AP/BP treated frontline with AZA at the standard dosage (75 mg/m
    MeSH term(s) Aged ; Antimetabolites, Antineoplastic/therapeutic use ; Azacitidine/therapeutic use ; Blast Crisis/diagnosis ; Blast Crisis/drug therapy ; Female ; Humans ; Hydroxyurea/therapeutic use ; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative/diagnosis ; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative/drug therapy ; Male ; Melphalan/therapeutic use ; Middle Aged ; Mutation ; Myeloproliferative Disorders/diagnosis ; Myeloproliferative Disorders/drug therapy ; Pipobroman/therapeutic use ; Polycythemia Vera/diagnosis ; Polycythemia Vera/drug therapy ; Primary Myelofibrosis/diagnosis ; Primary Myelofibrosis/drug therapy ; Prognosis ; Remission Induction ; Retrospective Studies ; Thrombocythemia, Essential/diagnosis ; Thrombocythemia, Essential/drug therapy ; Treatment Outcome
    Chemical Substances Antimetabolites, Antineoplastic ; Pipobroman (6Q99RDT97R) ; Azacitidine (M801H13NRU) ; Melphalan (Q41OR9510P) ; Hydroxyurea (X6Q56QN5QC)
    Language English
    Publishing date 2019-05-30
    Publishing country England
    Document type Journal Article ; Multicenter Study ; Observational Study
    ZDB-ID 604884-5
    ISSN 1099-1069 ; 0278-0232
    ISSN (online) 1099-1069
    ISSN 0278-0232
    DOI 10.1002/hon.2635
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1816: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Decreased NOTCH1 Activation Correlates with Response to Ibrutinib in Chronic Lymphocytic Leukemia.

    Del Papa, Beatrice / Baldoni, Stefano / Dorillo, Erica / De Falco, Filomena / Rompietti, Chiara / Cecchini, Debora / Cantelmi, Maria Grazia / Sorcini, Daniele / Nogarotto, Manuel / Adamo, Francesco Maria / Mezzasoma, Federica / Silva Barcelos, Estevão Carlos / Albi, Elisa / Iacucci Ostini, Roberta / Di Tommaso, Ambra / Marra, Andrea / Montanaro, Guido / Martelli, Maria Paola / Falzetti, Franca /
    Di Ianni, Mauro / Rosati, Emanuela / Sportoletti, Paolo

    Clinical cancer research : an official journal of the American Association for Cancer Research

    2019  Volume 25, Issue 24, Page(s) 7540–7553

    Abstract: Purpose: Ibrutinib, a Bruton tyrosine kinase inhibitor (BTKi), has improved the outcomes of chronic lymphocytic leukemia (CLL), but primary resistance or relapse are issues of increasing significance. While the predominant mechanism of action of BTKi is ...

    Abstract Purpose: Ibrutinib, a Bruton tyrosine kinase inhibitor (BTKi), has improved the outcomes of chronic lymphocytic leukemia (CLL), but primary resistance or relapse are issues of increasing significance. While the predominant mechanism of action of BTKi is the B-cell receptor (BCR) blockade, many off-target effects are unknown. We investigated potential interactions between BCR pathway and NOTCH1 activity in ibrutinib-treated CLL to identify new mechanisms of therapy resistance and markers to monitor disease response.
    Experimental design: NOTCH activations was evaluated either
    Results: In vitro
    Conclusions: We demonstrated a strong clinical activity of ibrutinib in a real-life context. The ibrutinib clinical efficacy was associated with NOTCH1 activity downregulation that deepened over time. Our data point to NOTCH1 as a new molecular partner in BCR signaling with potential to further improve CLL-targeted treatments.
    MeSH term(s) Apoptosis ; Biomarkers, Tumor/metabolism ; Drug Resistance, Neoplasm ; Humans ; Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy ; Leukemia, Lymphocytic, Chronic, B-Cell/metabolism ; Leukemia, Lymphocytic, Chronic, B-Cell/pathology ; Protein Kinase Inhibitors/pharmacology ; Pyrazoles/pharmacology ; Pyrimidines/pharmacology ; Receptor, Notch1/genetics ; Receptor, Notch1/metabolism ; Receptors, Antigen, B-Cell/genetics ; Receptors, Antigen, B-Cell/metabolism ; Signal Transduction ; Treatment Outcome ; Tumor Cells, Cultured
    Chemical Substances Biomarkers, Tumor ; NOTCH1 protein, human ; Protein Kinase Inhibitors ; Pyrazoles ; Pyrimidines ; Receptor, Notch1 ; Receptors, Antigen, B-Cell ; ibrutinib (1X70OSD4VX)
    Language English
    Publishing date 2019-10-02
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1225457-5
    ISSN 1557-3265 ; 1078-0432
    ISSN (online) 1557-3265
    ISSN 1078-0432
    DOI 10.1158/1078-0432.CCR-19-1009
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4223: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top